TriangleNCT01970865 · OUTCOME
Overall Survival (OS) (Phase 1)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 3 years
What was measured
OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
Analysis population: The intent-to-treat (ITT) analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. Here, "Number Analyzed" signifies participants analyzed for this outcome measure.
Groups in this outcome
ALK Positive Population (Phase 1)
This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.
ROS1 Positive Population (Phase 1)
This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.
| Group | Source count |
|---|---|
| ALK Positive Population (Phase 1) | 41 |
| ROS1 Positive Population (Phase 1) | 12 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ALK Positive Population (Phase 1) | 22.3 | Not reported | 11.4 | NA | A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics. |
| ROS1 Positive Population (Phase 1) | NA | Not reported | 4.7 | NA | A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics. |
Complete source fields
- classes
- categories
- measurements
- comment
- A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics.
- group Id
- OG000
- lower Limit
- 11.4
- upper Limit
- NA
- value
- 22.3
- comment
- A large proportion of participants in the analysis set had their OS data censored, and number of participants dead by the cutoff date of this report was small, so it's impossible to derive such summary statistics.
- group Id
- OG001
- lower Limit
- 4.7
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 41
- group Id
- OG001
- value
- 12
- units
- Participants
- description
- OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.
- id
- OG000
- title
- ALK Positive Population (Phase 1)
- description
- This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.
- id
- OG001
- title
- ROS1 Positive Population (Phase 1)
- param Type
- MEDIAN
- population Description
- The intent-to-treat (ITT) analysis set included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922. Here, "Number Analyzed" signifies participants analyzed for this outcome measure.
- reporting Status
- POSTED
- time Frame
- 3 years
- title
- Overall Survival (OS) (Phase 1)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice